“N” biomarker category (structural MRI, FDG-PET, and CSF total tau) was also proposed to define the presence of neuronal injury and to provide powerful tools to assess the risk of progression from preclinical to prodromal AD, and from prodromal AD to dementia [14]. This evidence concerns the gene MAPT and dementia.